It is noteworthy that, owing to the contribution of TKIs and an enhanced understanding of the influence of the BCR-ABL mutational profile on drug efficacy, CML is presently recognized as a chronic ailment. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.